AB0125 The Effect of Gv1001, A Peptide Vaccine, in Animal Model of Rheumatoid Arthritis. (10th June 2014)

• Record Type: Journal Article
• Authors: Choi, I.A.; Choi, J.Y.; Kim, J.S.; Oh, S.-Y.; Kim, S.; Lee, E.Y.
• Is Part Of: Annals of the rheumatic diseases. Volume 73:Supplement 2(2014)
• Page Start: 845
• Page End: 845
• Publication Date: 2014-06-10
• Subjects: Rheumatism -- Periodicals; 616.723005
• DOI: 10.1136/annrheumdis-2014-eular.2421
• Languages: English
• ISSNs: 0003-4967

Abstract

Abstract : Background: GV1001 is a 16-mer peptide developed as a cancer vaccine to prime the immune system to recognize telomerase. Besides its role as a cancer vaccine, GV1001 has anti-inflammatory effects in in-vitro experiments using macrophage or monocyte. Objectives: We evaluated the effect of GV1001 to inhibit joint inflammation in animal model of RA. Methods: 5-week old BDA/1 mice were used to induce collagen induced arthritis (CIA). Mice were immunized with bovine type II collagen on day 1 and boosted on day 21. Treatments with GV1001 (0.2 nM, 1 nM, 2 nM, 5 nM, and 10 nM) or placebo were started on day 21, three times in alternative week (on day 21, 23, 25 and day 35, 37, 39). Weight and arthritis index of the mice using a standardized grading scale (0–3) were monitored from day 21. Observation finished on day 42, harvesting mouse serum and joints for further analysis. Histological scores of joint damage were assessed using 0–3 grading scale. Results: Mean arthritis index on day 42 was lower in 0.2 nM GV1001 group compared to placebo group without statistical significance (p=0.1). Histologic assessment after low dose GV1001 treatment showed a tendency to have a lower histologic score (Fig. 1 ). Serum IL-6 level was significantly lower in 1 nM (the same concentration used as human cancer vaccine) and 0.2 nM GV1001 group (p<0.01, both) compared to placebo group. Conclusions: In this study, we explored the novel therapeutic effect of GV1001 in animal model of rheumatoid arthritis. Protective effect of GV1001 was not dose dependent and effective in 1 nM, which is the same concentration used as human cancer vaccine and the lower dose as 0.2 nM. These results suggest the therapeutic potential of GV1001 as a new RA treatment. Disclosure of Interest: I. A. Choi: None declared, J. Y. Choi: None declared, J. S. Kim: None declared, S.-Y. Oh Employee of: KAEL-GemVax, developer of GV1001, S. Kim Shareholder of: KAEL-GemVax, developer of GV1001, E. Y. Lee: None declared DOI: 10.1136/annrheumdis-2014-eular.2421